Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

June 15, 2021

- SYNB1618 Phase 2 study in patients with PKU ongoing with readout expected in 2H 2021; SYNB1934 demonstrates 2-fold improvement in activity in multiple pre-clinical models -

- SYNB8802 Phase 1 study ongoing; readout from Part B placebo-controlled crossover in patients with Enteric Hyperoxaluria expected in 2H 2021 -

CAMBRIDGE, Mass., June 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of the investigational Synthetic Biotic medicine™ SYNB8802 for the treatment of Enteric Hyperoxaluria and on SYNB1934, an evolved strain of Synthetic Biotic medicine SYNB1618, for the treatment of Phenylketonuria (PKU) during the Synthetic Biology: Engineering, Evolution & Design (SEED) conference, being held virtually June 15-18, 2021.

The two posters will be available throughout the duration of the conference:

- Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU)
- Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria

SYNB1934 is an evolved strain of SYNB1618, developed to provide a potentially greater degree of phenylalanine (Phe)-lowering relative to SYNB1618. Data from preclinical *in vivo* and *in vitro* studies demonstrated a greater than 2-fold improvement in the ability of SYNB1934 to metabolize Phe compared to SYNB1618.

"The progression of SYNB1934 highlights Synlogic's ability to use synthetic biology to rapidly design and optimize Synthetic Biotic medicines with the potential for greater patient benefit. Building on SYNB1618, our team has iterated to generate a new fit-for-purpose strain. We look forward to continuing to progress SYNB1934 and to potentially providing people living with PKU new therapeutic options," said Dr. David Hava, Ph.D, Synlogic's Chief Scientific Officer.

SYNB8802 is an oral investigational drug for the treatment of Enteric Hyperoxaluria. The data presented characterizes *in vitro* and *in vivo* activity of SYNB8802 and, using proprietary gut simulation techniques, provides evidence of strain activity throughout the GI tract.

About Enteric Hyperoxaluria
Enteric Hyperoxaluria is an acquired metabolic disorder caused by increased absorption of dietary oxalate, which is present in many healthy foods, making it almost impossible to control with diet alone. Enteric Hyperoxaluria often occurs as a result of a primary insult to the bowel, such as inflammatory bowel disease, short bowel syndrome, or as a result of surgical procedures such as Roux-en-Y bariatric weight-loss surgery. Enteric Hyperoxaluria results in dangerously high levels of urinary oxalate, which causes progressive kidney damage, kidney stone formation, and nephrocalcinosis. There are no approved treatment options.

About PKU
Phenylketonuria (PKU) is an inherited metabolic disease that manifests at birth and is marked by an inability to break down phenylalanine (Phe), an amino acid that is commonly found in many foods. Left untreated, high levels of Phe become toxic and can lead to serious neurological and neuropsychological problems affecting the way a person thinks, feels, and acts. Due to the seriousness of these symptoms, infants are screened at birth in many countries to ensure early diagnosis and treatment to avoid intellectual disability and other complications.

About Synlogic
Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic™ medicines that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria. The company is also building a portfolio of partner-able assets in immunology and oncology. Learn more about Synlogic's programs and pipeline by visiting https://www.synlogictx.com/.

Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases including: cancer, inborn errors of metabolism, and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of SYNB1618 and

availability of clinical trial data including Phase 2 data of SYNB1618 for the treatment of PKU. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

View original content:http://www.prnewswire.com/news-releases/synlogic-presents-additional-preclinical-data-on-therapeutic-candidates-synb1934-for-phenylketonuria-pku-and-synb8802-for-enteric-hyperoxaluria-at-synthetic-biology-engineering-evolution--design-seed-conference-301312771.html

SOURCE Synlogic, Inc.

Media Contact: Christen Baglaneas, Synlogic, Inc., Phone: 617-401-9152, Email: christen.baglaneas@synlogictx.com; Investor Contact: Daniel Rosan, Synlogic, Inc., Phone: 617-401-9152, Email: dan.rosan@synlogictx.com